Literature DB >> 27744478

Guilty by dissociation-development of gas chromatography-mass spectrometry (GC-MS) and other rapid screening methods for the analysis of 13 diphenidine-derived new psychoactive substances (NPSs).

Pierre M Geyer1, Matthew C Hulme1, Joseph P B Irving1, Paul D Thompson1, Ryan N Ashton1, Robert J Lee1, Lucy Johnson1, Jack Marron1, Craig E Banks2, Oliver B Sutcliffe3.   

Abstract

The prevalence of new psychoactive substances (NPSs) in forensic casework has increased prominently in recent years. This has given rise to significant legal and analytical challenges in the identification of these substances. The requirement for validated, robust and rapid testing methodologies for these compounds is obvious. This study details the analysis of 13 synthesised diphenidine derivatives encountered in casework using presumptive testing, thin layer chromatography and gas chromatography-mass spectrometry (GC-MS). Specifically, the validated GC-MS method provides, for the first time, both a general screening method and quantification of the active components for seized solid samples, both in their pure form and in the presence of common adulterants. Graphical Abstract Chemical synthesis and forensic analysis of 13 diphenidine-derived new psychoactive substance(s).

Entities:  

Keywords:  Characterisation (NMR, FT-IR); Diphenidine; GC–MS; Methoxphenidine; New psychoactive substances; Triage

Mesh:

Substances:

Year:  2016        PMID: 27744478     DOI: 10.1007/s00216-016-9969-y

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  7 in total

1.  Pharmacological characterizations of the 'legal high' fluorolintane and isomers.

Authors:  Jason Wallach; Tristan Colestock; Julià Agramunt; Matt D B Claydon; Michael Dybek; Nadine Filemban; Muhammad Chatha; Adam L Halberstadt; Simon D Brandt; David Lodge; Zuner A Bortolotto; Adeboye Adejare
Journal:  Eur J Pharmacol       Date:  2019-05-29       Impact factor: 4.432

Review 2.  Interpol review of controlled substances 2016-2019.

Authors:  Nicole S Jones; Jeffrey H Comparin
Journal:  Forensic Sci Int Synerg       Date:  2020-05-24

3.  Rapid Identification of Novel Psychoactive and Other Controlled Substances Using Low-Field 1H NMR Spectroscopy.

Authors:  Lysbeth H Antonides; Rachel M Brignall; Andrew Costello; Jamie Ellison; Samuel E Firth; Nicolas Gilbert; Bethany J Groom; Samuel J Hudson; Matthew C Hulme; Jack Marron; Zoe A Pullen; Thomas B R Robertson; Christopher J Schofield; David C Williamson; E Kate Kemsley; Oliver B Sutcliffe; Ryan E Mewis
Journal:  ACS Omega       Date:  2019-04-19

4.  The medicinal plant Tabebuia impetiginosa potently reduces pro-inflammatory cytokine responses in primary human lymphocytes.

Authors:  Rachael Y M Ryan; Alejandra Fernandez; Yide Wong; John J Miles; Ian E Cock
Journal:  Sci Rep       Date:  2021-03-09       Impact factor: 4.379

5.  Detection of newly emerging psychoactive substances using Raman spectroscopy and chemometrics.

Authors:  Jesus Calvo-Castro; Amira Guirguis; Eleftherios G Samaras; Mire Zloh; Stewart B Kirton; Jacqueline L Stair
Journal:  RSC Adv       Date:  2018-09-12       Impact factor: 4.036

6.  Chemical synthesis, characterisation and in vitro and in vivo metabolism of the synthetic opioid MT-45 and its newly identified fluorinated analogue 2F-MT-45 with metabolite confirmation in urine samples from known drug users.

Authors:  Craig McKenzie; Oliver B Sutcliffe; Kevin D Read; Paul Scullion; Ola Epemolu; Daniel Fletcher; Anders Helander; Olof Beck; Alexia Rylski; Lysbeth H Antonides; Jennifer Riley; Shannah A Smith; Niamh Nic Daeid
Journal:  Forensic Toxicol       Date:  2018-04-05       Impact factor: 4.096

7.  Activation of μ-opioid receptors by MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine) and its fluorinated derivatives.

Authors:  Daniel T Baptista-Hon; Mark Smith; Samuel Singleton; Lysbeth H Antonides; Niamh Nic Daeid; Craig McKenzie; Tim G Hales
Journal:  Br J Pharmacol       Date:  2020-05-13       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.